IP Library Granted Patent US 7,056,902
Granted Patent B2
US 7,056,902 · App. 10/337,914 · Granted Jun 6, 2006

4-dedimethylamino tetracycline compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,056,902
App. No.
10/337,914
Granted
Jun 6, 2006
Kind
B2
Abstract

The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Claims (29)

1. A tetracycline compound of formula IV:

wherein:

X is CHC(R 13 Y′Y), or CR 6′ R 6 ;

R 2 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic or heteroaromatic;

R 7′ and R 7″ are each alkyl;

R 4 and R 4′ are each independently alkyl, alkenyl, alkynyl, aryl, hydroxyl, alkoxy, halogen, hydrogen, or taken together to form the oxygen of a carbonyl;

R 2′ , R 3 , R 10 , R 11 and R 12 are each hydrogen;

R 5 is hydroxyl hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;

R 6 and R 6′ are independently hydrogen, methylene, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R 7 is NR 7′ R 7″ ;

R 9 is alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amido, acyl, arylalkenyl, arylalkynyl, thionitroso, or —(CH 2 ) 0-3 NR 9c C(=Z′)ZR 9a ;

Z is CR 9d R 9e , S, NR 9b or O;

Z′ is NR 9f , O or S;

R 9a , R 9b , R 9c , R 9d , R 9e and R 9f are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic or heteroaromatic;

R 8 is hydrogen, hydroxyl, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R 13 is hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

Y′ and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and amides thereof.

2. The tetracycline compound of claim 1 , wherein R 9 is acyl.

3. The tetracycline compound of claim 2 , wherein R 9 is acetyl.

4. The tetracycline compound of claim 1 , wherein R 4 and R 4′ are each hydrogen or the oxygen of a carbonyl group; X is CR 6 R 6′ ; R 2 , R 2′ , R 5 , R 6 , R 6′ , R 8 , R 10 , R 11 , and R 12 are each hydrogen; and R 7′ and R 7″ are each lower alkyl.

5. A tetracycline compound of claim 1 , wherein the compound is:

6. The tetracycline compound of claim 1 , wherein R 7 is dimethylamino.

7. The tetracycline compound of claim 1 , wherein R 9 is substituted or unsubstituted aryl.

8. The tetracycline compound of claim 1 , wherein R 9 is substituted or unsubstituted alkyl.

9. The tetracycline compound of claim 1 , wherein R 9 is substituted or unsubstituted alkynyl.

10. The tetracycline compound of claim 1 , wherein R 4 , R 4′ , and R 5 are each hydrogen.

11. A substituted tetracycline compound selected from the group consisting of:

and pharmaceutically acceptable salts, esters and amides thereof.

12. A pharmaceutical composition comprising a therapeutically effective amount of a tetracycline compound of claim 1 and a pharmaceutically acceptable carrier.

Assignments (9)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 065001/0917 Recorded May 22, 2025
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 071343/0407 →
SECURITY INTEREST Recorded Sep 22, 2023
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 065001/0917 →
TERMINATION OF LIEN ON PATENTS Recorded Dec 23, 2014
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034700/0377 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
SECURITY INTEREST Recorded Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →
NOTICE Recorded Mar 8, 2013
From: PARATEK PHARMACEUTICALS, INC.
To: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
Reel/Frame 029940/0106 →
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2009
From: MIDCAP FINANCIAL, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 023348/0621 →
SECURITY AGREEMENT Recorded Jul 6, 2009
From: PARATEK PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL, LLC
Reel/Frame 022917/0112 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2003
From: NELSON, MARK L.; OHEMENG, KWASI
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 014120/0584 →